Riten Kumar/LinkedIn
Dec 9, 2025, 13:27
Riten Kumar: Highlights From Day 2 of ASH25
Riten Kumar, Associate Professor of Pediatrics at Harvard Medical School and Director of Thrombosis and Anticoagulation at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shared on LinkedIn:
“Highlights of day 2 of ASH25 – excellent lectures on PFD and HHT, long term data on gene therapy and altuviiio in hemophilia. Particularly enjoyed the the session on arterial thrombosis for hematologists. Interesting data on iv iron infection. It was also great to see some of the work from the ASH/ISTH guidelines work get presented…… And of course, hematologists can groove!”
All from ASH25 featured in Hemostasis Today.
-
May 8, 2026, 09:25Athma Dias: Limitations of PT and APTT in Predicting Thrombotic Risk
-
May 8, 2026, 09:12Abhishek Kumar: New Horizons in Hemophilia B Treatment and Prevention
-
May 8, 2026, 08:19Augustina Isioma Ikusemoro: Thalassaemia is not Just a Blood Disorder – It is a Public Health Priority
-
May 8, 2026, 06:24Transforming Thrombosis Management With Antithrombotic Stewardship – Anticoagulation Forum
-
May 8, 2026, 06:03Risk-Stratified HRT Use Following VTE – NBCA
-
May 7, 2026, 17:56The Latest Clinical Data Shaping The Evolving Landscape of Hemophilia Treatment – EAHAD
-
May 7, 2026, 17:31Talha Badar: New Classical Hematology Chapter on Bleeding and Thrombosis
-
May 7, 2026, 17:26Maria Τektonidou: Gene Network Analysis Identifies STAT1 in Thrombotic APS
-
May 7, 2026, 17:23Sonu Bhaskar: Inflammatory Biomarkers in Acute Cerebral Venous Sinus Thrombosis